Previously published September 26, 2022
ASCO is saddened by the death of oncology luminary and past Board of Directors member Nicholas J. Vogelzang, MD, FACP, FASCO, on September 20, 2022, at the age of 72.
Dr. Vogelzang was most recently a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He served as medical director of the Research Executive Committee and associate chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. He previously served as director of the Nevada Cancer Institute, and as director of the University of Chicago Cancer Research Center and the institution’s first Fred C. Buffett Professor in Medicine.
Among his many scientific achievements, Dr. Vogelzang will be remembered for his leadership on the clinical trials that led to the approvals of pemetrexed in combination with cisplatin for mesothelioma and abiraterone in combination with prednisone for metastatic castration-resistant prostate cancer, bringing renewed hope to patients with these diseases.
Read more in ASCO Connection.
